Q3 2020 Sales Performance

From EVOLUTION to REVOLUTION: the 2DR era gsk Current standard of care HAART/legacy drugs Dolutegravir-based regimens Tivicay Triumeq Legacy ARV drug portfolio abacavir/lamivudine, maraviroc and others New treatment paradigm 2DR = Two-drug regimens Juluca: dolutegravir/rilpivirine Dovato: dolutegravir/lamivudine Long-acting treatment regimens Cabenuva**: cabotegravir + rilpivirine Search for remission and cure Prevention cabotegravir long-acting* New MOA Rukobia: Attachment inhibitor (fostemsavir) Maturation inhibitor portfolio** Capsid inhibitor** Broadly neutralizing AB (N6LS)** *Investigational treatments ** Cabenuva approved in Canada *Discovery programme Pipeline Strategy 27

View entire presentation